Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

GLP1-based obesity medicines, such as Ozempic and Wegovy, have surged in popularity and become the subject of intense public ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

A new report finds half of adults in the United States could be eligible for popular weight loss drugs. KYW medical editor Dr ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...

This repeated cross-sectional study including 69.2 million obesity management drug dispensed prescriptions revealed an ...

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...